ARTICLEhttps://harbor.dev.pubfactory.com/view/journals/jnccn/2/1/article-p31.xmlNMSC in Organ Transplant Recipients and Other High-Risk Groups2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/2/1/article-p31.pdf2026-04-18NMSC in Organ Transplant Recipients and Other High-Risk Groupshttps://harbor.dev.pubfactory.com/view/journals/jnccn/2/1/article-p6.xmlBasal Cell and Squamous Cell Skin Cancers Clinical Practice Guidelines in Oncology2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/2/1/article-p89.xmlTreatment Options for Merkel Cell Carcinoma2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/2/1/article-p89.pdf2026-04-18Treatment Options for Merkel Cell Carcinomahttps://harbor.dev.pubfactory.com/view/journals/jnccn/2/1/article-p61.xmlPoint: Interferon-α for Adjuvant Therapy for Melanoma Patients2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/2/1/article-p61.pdf2026-04-18Point: Interferon-α for Adjuvant Therapy for Melanoma Patientshttps://harbor.dev.pubfactory.com/view/journals/jnccn/2/1/article-p69.xmlCounterpoint: The Case Against Adjuvant High-Dose Interferon-α for Melanoma Patients2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/2/1/article-p69.pdf2026-04-18Counterpoint: The Case Against Adjuvant High-Dose Interferon-α for Melanoma Patientshttps://harbor.dev.pubfactory.com/view/journals/jnccn/2/1/article-p80.xmlMerkel Cell Carcinoma Clinical Practice Guidelines in Oncology2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/2/1/article-p74.xmlDermatofibrosarcoma Protuberans Clinical Practice Guidelines in Oncology2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/2/1/article-p46.xmlMelanoma Clinical Practice Guidelines in Oncology2026-04-18